文献速递胸部肿瘤

围手术期度伐利尤单抗治疗可切除非小细胞肺癌:III期AEGEAN试验更新结果

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
PubMed 文献 · J Clin Oncol · 2026-08-28

AEGEAN研究是一项III期双盲安慰剂对照试验,评估围手术期度伐利尤单抗联合新辅助化疗对比单纯新辅助化疗在可切除非小细胞肺癌(R-NSCLC)中的疗效。第二次计划中期分析显示,度伐利尤单抗组无事件生存(EFS)获益持续(HR 0.69,95%CI 0.55-0.88),无病生存(DFS)和总生存(OS)数值上倾向获益。安全性特征与单药已知一致。

要点

  • 围手术期度伐利尤单抗联合新辅助化疗显著改善EFS(HR 0.69)。
  • DFS和OS数值上倾向度伐利尤单抗组,但OS未达统计学显著。
  • 辅助阶段度伐利尤单抗组3/4级不良事件发生率为15.4%。

核心结论

  • 围手术期度伐利尤单抗联合新辅助化疗对比单纯新辅助化疗,在可切除非小细胞肺癌中持续显示EFS获益。
  • DFS和OS数值上倾向度伐利尤单抗组,但OS的95%CI跨越1,未显示统计学显著改善。

研究设计与样本

  • III期、双盲、安慰剂对照研究,患者为初治可切除非小细胞肺癌(II-IIIB期[N2])。
  • 患者1:1随机分配至新辅助铂类化疗联合度伐利尤单抗或安慰剂(每3周一次,共4周期),术后辅助度伐利尤单抗或安慰剂(每4周一次,共12周期)。
  • 疗效分析基于改良意向治疗人群(n=740),排除了记录有EGFR/ALK异常的患者;DFS分析基于其切除亚组。

主要发现

  • 截至2024年5月10日(中位随访25.9个月),EFS获益持续,HR为0.69(95%CI 0.55-0.88)。
  • DFS数值上倾向度伐利尤单抗组,HR为0.66(95%CI 0.47-0.92)。
  • OS数值上倾向度伐利尤单抗组,HR为0.89(95%CI 0.70-1.14)。
  • 辅助治疗期间,度伐利尤单抗组和安慰剂组最大3/4级不良事件发生率分别为15.4%和10.6%。

临床怎么用

  • 结果进一步支持围手术期度伐利尤单抗联合新辅助化疗作为可切除非小细胞肺癌的新治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In AEGEAN, perioperative durvalumab plus neoadjuvant chemotherapy, versus neoadjuvant chemotherapy alone, significantly improved event-free survival (EFS) and pathologic complete response in patients with resectable non-small cell lung cancer (R-NSCLC), with a safety profile consistent with the individual agents. We report EFS from a second planned interim analysis, interim disease-free survival (DFS) and overall survival (OS), and safety, after all patients completed/discontinued treatment. In this phase III, double-blind, placebo-controlled study, patients with treatment-naïve R-NSCLC (stage II-IIIB [N2]) were randomly assigned (1:1) to neoadjuvant platinum-based chemotherapy plus durvalumab/placebo (once every 3 weeks, four cycles) presurgery and then adjuvant durvalumab/placebo (once every 4 weeks, 12 cycles). Efficacy was analyzed in the modified intention-to-treat population (n = 740; for DFS, its resected subpopulation), which excluded patients with documented EGFR/ALK aberrations. As of May 10, 2024 (median follow-up, 25.9 months [censored patients]), EFS benefit favoring the durvalumab arm remained consistent (hazard ratio [HR], 0.69 [95% CI, 0.55 to 0.88]). Numerical improvement in DFS (HR, 0.66 [95% CI, 0.47 to 0.92]) and OS (HR, 0.89 [95% CI, 0.70 to 1.14]) favored the durvalumab arm. Maximum grade 3/4 adverse events occurred in 15.4% and 10.6% of the durvalumab and placebo arms, respectively, during adjuvant treatment. These results further support perioperative durvalumab plus neoadjuvant chemotherapy as a new treatment option.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Heymach JV, He J, Harpole D, et al. Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial. J Clin Oncol. 2026. PMID: 42664473. doi:10.1200/JCO-25-02659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。